Clinical Trials
12 trialsNCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04672434 2024-12-09
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT05538572 2024-07-01
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
Phase 1 Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03652077 2021-11-15
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT03538028 2020-10-30
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT00006981 2015-04-30
Immunotoxin Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00066651 2015-04-30
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020579 2012-03-15
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed